Zalicus has drawn the remaining $8.5m from its $20m secured credit facility with Oxford Finance to fund ion channel clinical development.
Zalicus CEO Mark Corrigan said they look forward to report data from these Phase 1 studies in 2012.
"Z944 is the second study emanating from our ion channel discovery platform this month, following closely on the heels of Z160, an N-type calcium channel blocker," Corrigan added.